Protein Kinase C Zeta Regulates Human Pancreatic Cancer Cell Transformed Growth and Invasion through a STAT3-Dependent Mechanism

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Butler, Amanda M ^a   Scotti Buzhardt, Michele L ^a   Li, Shuhua ^a   Smith, Kristin E ^a   Fields, Alan P ^a   Murray, Nicole R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C ZETA; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SIZE; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAPHRAGM METASTASIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY METASTASIS; LIVER METASTASIS; MALE; MESENTERY METASTASIS; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY MECHANISM; RISK REDUCTION; RNA INTERFERENCE; TUMOR INVASION; TUMOR NECROSIS;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PHENOTYPE; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN;

EID: 84883178112     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072061     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Lebedeva IV, Sarkar D, Su ZZ, Gopalkrishnan RV, Athar M, et al. (2006) Molecular target-based therapy of pancreatic cancer. Cancer Res 66: 2403-2413.
3. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, et al. (1982) Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 257: 7847-7851.
4. Galvez AS, Duran A, Linares JF, Pathrose P, Castilla EA, et al. (2009) Protein kinase Cζ represses the interleukin-6 promoter and impairs tumorigenesis in vivo. Molecular and Cellular Biology 29: 104-115.
5. Murray NR, Jamieson L, Yu W, Zhang J, Gokmen-Polar Y, et al. (2004) Protein kinase C{iota} is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol 164: 797-802.
6. Murray NR, Weems J, Braun U, Leitges M, Fields AP, (2009) Protein kinase C betaII and PKCiota/lambda: collaborating partners in colon cancer promotion and progression. Cancer Res 69: 656-662.
7. Oster H, Leitges M, (2006) Protein kinase C alpha but not PKCzeta suppresses intestinal tumor formation in ApcMin/+ mice. Cancer Res 66: 6955-6963.
8. Caino MC, Lopez-Haber C, Kissil JL, Kazanietz MG, (2012) Non-small cell lung carcinoma cell motility, rac activation and metastatic dissemination are mediated by protein kinase C epsilon. PLoS ONE 7: e31714.
9. Gonzalez-Guerrico AM, Meshki J, Xiao L, Benavides F, Conti CJ, et al. (2005) Molecular mechanisms of protein kinase C-induced apoptosis in prostate cancer cells. J Biochem Mol Biol 38: 639-645.
10. Fields AP, Murray NR, (2008) Protein kinase C isozymes as therapeutic targets for treatment of human cancers. Adv Enzyme Regul 48: 166-178.
11. Leitges M, Sanz L, Martin P, Duran A, Braun U, et al. (2001) Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell 8: 771-780.
12. Soloff RS, Katayama C, Lin MY, Feramisco JR, Hedrick SM, (2004) Targeted deletion of protein kinase C lambda reveals a distribution of functions between the two atypical protein kinase C isoforms. J Immunol 173: 3250-3260.
13. Regala RP, Davis RK, Kunz A, Khoor A, Leitges M, et al. (2009) Atypical protein kinase Cι is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Research 69: 7603-7611.
14. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, et al. (2005) Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 65: 8905-8911.
15. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, et al. (2005) Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 102: 12519-12524.
16. Scotti ML, Bamlet WR, Smyrk TC, Fields AP, Murray NR, (2010) Protein kinase Cι is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Research 70: 2064-2074.
17. Nazarenko I, Jenny M, Keil J, Gieseler C, Weisshaupt K, et al. (2010) Atypical protein kinase C zeta exhibits a proapoptotic function in ovarian cancer. Mol Cancer Res 8: 919-934.
18. Mustafi R, Cerda S, Chumsangsri A, Fichera A, Bissonnette M, (2006) Protein Kinase-zeta inhibits collagen I-dependent and anchorage-independent growth and enhances apoptosis of human Caco-2 cells. Mol Cancer Res 4: 683-694.
19. Calcagno SR, Li S, Colon M, Kreinest PA, Thompson EA, et al. (2008) Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. Int J Cancer 122: 2462-2470.
20. Frederick LA, Matthews JA, Jamieson L, Justilien V, Thompson EA, et al. (2008) Matrix metalloproteinase-10 is a critical effector of protein kinase Cι-Par6α-mediated lung cancer. Oncogene 27: 4841-4853.
21. Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, et al. (2005) Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 280: 31109-31115.
22. Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, et al. (2006) The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 12: 6170-6178.
23. Calcagno SR, Li S, Shahid MW, Wallace MB, Leitges M, et al. (2011) Protein kinase C iota in the intestinal epithelium protects against dextran sodium sulfate-induced colitis. Inflamm Bowel Dis 17: 1685-1697.
24. Haga S, Terui K, Zhang HQ, Enosawa S, Ogawa W, et al. (2003) Stat3 protects against Fas-induced liver injury by redox-dependent and-independent mechanisms. J Clin Invest 112: 989-998.
25. Frank DA, (2007) STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 251: 199-210.
26. Turkson J, Jove R, (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19: 6613-6626.
27. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, et al. (2011) Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19: 456-469.
28. Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, et al. (2011) STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71: 5020-5029.
29. Zhang X, Yue P, Page BD, Li T, Zhao W, et al. (2012) Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 109: 9623-9628.
30. Cohen EE, Lingen MW, Zhu B, Zhu H, Straza MW, et al. (2006) Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res 66: 6296-6303.
31. Valkova C, Mertens C, Weisheit S, Imhof D, Liebmann C, (2010) Activation by tyrosine phosphorylation as a prerequisite for protein kinase Czeta to mediate epidermal growth factor receptor signaling to ERK. Mol Cancer Res 8: 783-797.
32. Xiao H, Bai XH, Wang Y, Kim H, Mak AS, et al. (2013) MEK/ERK pathway mediates PKC activation-induced recruitment of PKCzeta and MMP-9 to podosomes. J Cell Physiol 228: 416-427.
33. Fernandez N, Caloca MJ, Prendergast GV, Meinkoth JL, Kazanietz MG, (2000) Atypical protein kinase C-zeta stimulates thyrotropin-independent proliferation in rat thyroid cells. Endocrinology 141: 146-152.
34. Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, et al. (2010) A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol 79: 1398-1409.
35. Luna-Ulloa LB, Hernandez-Maqueda JG, Santoyo-Ramos P, Castaneda-Patlan MC, Robles-Flores M, (2011) Protein kinase C zeta is a positive modulator of canonical Wnt signaling pathway in tumoral colon cell lines. Carcinogenesis 32: 1615-1624.
36. Yao S, Bee A, Brewer D, Dodson A, Beesley C, et al. (2010) PRKC-zeta Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention. Genes Cancer 1: 444-464.
37. Guo H, Gu F, Li W, Zhang B, Niu R, et al. (2009) Reduction of protein kinase C zeta inhibits migration and invasion of human glioblastoma cells. J Neurochem 109: 203-213.
38. Huang S, Ouyang N, Lin L, Chen L, Wu W, et al. (2012) HGF-induced PKCzeta activation increases functional CXCR4 expression in human breast cancer cells. PLoS ONE 7: e29124.
39. Valkov A, Sorbye SW, Kilvaer TK, Donnem T, Smeland E, et al. (2011) The prognostic impact of TGF-beta1, fascin, NF-kappaB and PKC-zeta expression in soft tissue sarcomas. PLoS ONE 6: e17507.
40. Nakanishi H, Brewer KA, Exton JH, (1993) Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 268: 13-16.
41. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, et al. (1998) Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281: 2042-2045.
42. Chou MM, Hou W, Johnson J, Graham LK, Lee MH, et al. (1998) Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr Biol 8: 1069-1077.
43. Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, et al. (2003) Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125: 891-905.
44. DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, et al. (2003) Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 22: 7781-7795.
45. Fukuda A, Wang SC, Morris JP, Folias AE, Liou A, et al. (2011) Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19: 441-455.
46. Jaganathan S, Yue P, Turkson J, (2010) Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther 333: 373-381.
47. Nam S, Wen W, Schroeder A, Herrmann A, Yu H, et al. (2012) Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Molecular oncology.
48. Yue P, Turkson J, (2009) Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 18: 45-56.
49. Frohner W, Lopez-Garcia LA, Neimanis S, Weber N, Navratil J, et al. (2011) 4-benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCzeta. J Med Chem 54: 6714-6723.
50. Lopez-Garcia LA, Schulze JO, Frohner W, Zhang H, Suss E, et al. (2011) Allosteric regulation of protein kinase PKCzeta by the N-terminal C1 domain and small compounds to the PIF-pocket. Chemistry & Biology 18: 1463-1473.